Here's something your pharmacy benefits manager will never admit: they make more money when your employees fill prescriptions than when they stay healthy.
Not catastrophically sick. That gets expensive for everyone. Just sick enough to need regular refills. Diabetes medications. Statins. Blood pressure pills. The chronic condition sweet spot where predictable revenue flows and nobody asks too many questions.
The entire system is designed to keep it that way.
The Hidden Profit Machine
Most HR leaders think they've got their PBM contract figured out. They've negotiated rebates, reviewed formulary tiers, maybe even pushed for generic-first policies. Check, check, check.
But what's actually happening behind the scenes is a different story entirely.
Three Profit Centers You're Funding
Spread pricing. Your PBM charges you $120 for a drug that costs them $40. You see "negotiated rate" on the invoice and assume you got a deal. That spread is their margin, collected on every script.
Rebates and fees. Drug manufacturers pay rebates to PBMs. Federal rules now push most of that money through to plan sponsors, but PBMs still keep value through administrative fees, rebate aggregator arrangements, and affiliated-pharmacy markups buried in contract language.
Volume economics. The more prescriptions your employees fill, the more spread and fees your PBM collects. Its revenue rises with utilization, which is the opposite of what you want.
Read that last one again.
Your PBM's financial success depends on your employees filling more prescriptions, not fewer. Their business model rewards higher utilization.
Does that sound like a partner aligned with your goal of reducing healthcare costs?
The Question That Changes Everything
There's a coverage strategy quietly transforming pharmacy benefits at forward-thinking companies. It starts with one question most employers never think to ask:
"What preventive action, taken 12–24 months ago, would have eliminated the need for this prescription?"
Pull your pharmacy spend report right now. Look at your top 10 drug costs.
You're almost certainly seeing:
- Metformin and other diabetes medications
- Statins for cholesterol management
- Lisinopril and blood pressure medications
- Antidepressants
- Inhalers and COPD medications
Now work backward from each one:
- Metformin ← Prediabetic A1C levels ← Missed metabolic screening ← No prevention pathway offered
- Statins ← High cholesterol ← Skipped lipid panel ← No nutritional intervention attempted
- Lisinopril ← Hypertension ← No BP monitoring program ← Diet and lifestyle never addressed
See the pattern?
When you dig into the data, the upstream gap is hard to miss. Only about 8% of adults complete all of the recommended preventive services, according to a Health Affairs analysis. The system never tried prevention in the first place.
Why Your Current Structure Guarantees This Outcome
Look at your typical pharmacy benefit design:
- $30 copay for the medication (after it's already needed)
- $0 copay for an annual physical (that roughly two-thirds of employees skip)
- Zero connection between the two
- No meaningful incentive to act early
- No consequence for ignoring prevention signals
You've accidentally built a system that pays for sickness and hopes for prevention. And hope, as they say, is not a strategy.
The Prevention-First Redesign
A small but growing number of employers are flipping the entire model. Instead of managing drug costs after the fact, they're eliminating drug needs before they start.
The redesign puts preventive care at $0 out of pocket, rewards completed preventive pathways immediately, and keeps medication affordable when prevention doesn't work. The goal is to prevent the prescription instead of negotiating its price.
Why This Approach Remains Rare
Most employers can't execute this shift because of three structural barriers:
Data fragmentation. Your PBM data sits in one system. Medical claims live in another. Wellness program tracking uses a third. Nobody connects them, so nobody can see the prevention-to-medication pathway clearly enough to redesign coverage around it.
Misaligned contracts. Your PBM's revenue model makes prevention financially irrational for them. They can't build you a system that reduces utilization. It would cut into their earnings model.
The "can't take benefits away" myth. Benefits teams worry about reducing drug coverage. But this shifts dollars upstream to prevent the need in the first place. Employees get healthier and keep more of what they'd otherwise spend at the pharmacy counter.
Five Coverage Strategies Your Broker Won't Mention
1. Audit for Prevention Leakage
Review every employee currently on chronic medication. For each one, document:
- Was prevention attempted before prescribing?
- How much time elapsed between diagnosis and first prescription?
- What early intervention could have changed the outcome?
You'll almost certainly discover that most chronic medications were prescribed without any documented prevention pathway. That points to a system design failure, not a clinical one. And system design is something you can fix.
2. Demand Preventive Care Code Integration
Your pharmacy system should automatically flag situations like:
- Diabetes medication prescribed without an A1C test on file
- Statin prescribed without a recent lipid panel
- Inhaler refilled by someone who skipped their pulmonary function test
This closes the loop between prevention and treatment automatically through proper data integration.
3. Restructure Coverage as Earned Access
Consider this design: $0 copay medications require completion of the relevant preventive actions first.
For example:
- Want $0 copay on blood pressure medication? Complete your annual BP monitoring and nutrition consultation.
- Want $0 copay on your inhaler? Complete your pulmonary function test.
- Want $0 copay on diabetes medication? Stay current with your A1C monitoring and diabetes education.
Employers testing this model see higher prevention completion and better medication adherence, because employees engage with their own health outcomes instead of passively filling prescriptions. Any design that ties coverage to health actions has to sit within federal wellness program rules, so work with benefits counsel before rolling it out.
4. Use Financial Incentives That Actually Work
Traditional wellness incentives fail for predictable reasons: they're small, they arrive months later, and they're disconnected from any meaningful health action.
What actually drives behavior change:
- An immediate reward for a completed action
- An amount that's meaningful enough to matter
- Rewards spendable on real health needs, such as FSA-eligible products and health devices
Instant rewards change behavior. Delayed abstractions just sound nice in benefits presentations.
5. Prepare for the Coming Migration
The next generation of pharmacy benefits won't be managed by traditional PBMs operating on spread pricing and rebate games. They'll be managed by integrated health-to-wealth platforms that:
- Track preventive care actions using standardized preventive care codes
- Automatically verify completion through claims data integration
- Reward employees instantly when they complete prevention pathways
- Generate data-driven recommendations for coverage model transitions
- Make preventing the prescription more profitable than filling it
This isn't theoretical future-talk. The technology exists today. Employers are already migrating to these aligned models and seeing the results in both health outcomes and balance sheets. WellthCare™, the first Health-to-Wealth™ Benefit System, is one such model, rewarding verified preventive actions with Store dollars and automatic retirement contributions while lowering employer claims.
FTC Settlements Are Rewriting PBM Economics
Employers don't have to redesign alone. The Federal Trade Commission sued the three largest PBMs (Caremark Rx, Express Scripts, and Optum Rx), alleging their rebating practices artificially inflated insulin list prices. The agency has since secured settlements with Express Scripts in February 2026 and Caremark in July 2026; the case against Optum Rx continues.
A second FTC staff report, published in January 2025, quantified the incentives this post describes. The three largest PBMs generated an estimated $1.4 billion from spread pricing, and their affiliated pharmacies collected $6.2 billion in dispensing revenue above the national average drug acquisition cost on the top 10 specialty generics alone. Federal law now requires PBMs to pass rebates and other manufacturer payments through to commercial plan sponsors.
The practical takeaway: the opacity that made volume-based PBM profit possible is already eroding. That doesn't mean employers can wait for enforcement to fix their drug spend. It means the employers who pair a prevention-first coverage design with transparent, pass-through contracts will get there first.
The Strategic Shift Every CFO Should Understand
There's a fundamental shift happening right now in benefits leadership:
Old question: "How do we negotiate better drug pricing?"
New question: "How do we help employees avoid needing drugs in the first place, and build real wealth in the process?"
When you restructure pharmacy benefits to reward prevention instead of just managing sickness:
- Employees get healthier (fewer medications needed over time)
- Employees build wealth (immediate rewards plus long-term savings)
- Employers reduce drug spend (transparent, aligned pharmacy models typically deliver 20–40% savings)
- Risk profiles improve (fewer chronic conditions developing in your population)
Everyone wins. The exception is the PBM that was profiting from the old broken model.
Your Monday Morning Action Plan
The goal is prevention, not just price negotiation.
Here's exactly what to do:
- Pull your top 20 drugs by total annual spend. Your PBM can provide this report (though they won't be happy about where this is heading).
- Map each to a preventive pathway. What action, taken 12–24 months early, could have reduced or eliminated this prescription need?
- Calculate potential savings. What would you save if you prevented just 30% of those prescriptions? Run the math. You'll be surprised.
- Ask the revealing question. "Why isn't my current system designed to make that happen?"
The answer to that last question will tell you everything you need to know about whether it's time to fundamentally redesign your prescription coverage model.
The Bottom Line
Your pharmacy benefit manager has one job: maximize their profit.
In the traditional model, that means maximizing your employees' prescription volume. More scripts equals more revenue. It's that simple.
You have a fundamentally different job: maximize your employees' health while minimizing unnecessary costs.
Those two objectives are incompatible.
The solution is structural realignment: moving from a sick-care management approach to a wealth-building prevention system where incentives point in the right direction.
The employers who figure this out first won't just save money on pharmacy benefits.
They'll fundamentally transform what healthcare means for their workforce, shifting from managing illness to building health and wealth simultaneously.
And that's a competitive advantage nobody can copy with better rebate negotiations.
Ready to see if your organization could benefit from prevention-first pharmacy coverage? Start by asking your current PBM one simple question: "How much additional revenue do you generate when our employees fill more prescriptions?"
Their answer, or more likely their carefully worded non-answer, will tell you everything you need to know about whose interests they're really serving.